Along with the extensive understanding of differentiated thyroid cancer (DTC)

its distinct molecular genotype and signaling pathway was revealed

which improved the development of molecular-targeted therapy. Regarding radioactive iodine-refractory DTC

multiple multikinase inhibitors including sorafenib and lenvatinib

which target vascular endothelial growth factor (VEGF) pathway

were proved to be effective. Moreover

selective inhibitors and redifferentiation agents were shown to be promising. In the future

individual genetic testing would provide more specific information in directing individualized molecular-targeted therapy.